MA51620B1 - Analogues de dihydrobenzofurane et d'inden en tant qu'inhibiteurs de sarcomes cardiaques - Google Patents

Analogues de dihydrobenzofurane et d'inden en tant qu'inhibiteurs de sarcomes cardiaques

Info

Publication number
MA51620B1
MA51620B1 MA51620A MA51620A MA51620B1 MA 51620 B1 MA51620 B1 MA 51620B1 MA 51620 A MA51620 A MA 51620A MA 51620 A MA51620 A MA 51620A MA 51620 B1 MA51620 B1 MA 51620B1
Authority
MA
Morocco
Prior art keywords
dihydrobenzofuran
inden
analogues
inhibitors
pharmaceutically acceptable
Prior art date
Application number
MA51620A
Other languages
English (en)
Other versions
MA51620A (fr
Inventor
Chihyuan Chuang
Bradley P. Morgan
Mark VANDERWAL
Wenyue Wang
Luke W. Ashcraft
Original Assignee
Cytokinetics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=65324663&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA51620(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cytokinetics, Inc. filed Critical Cytokinetics, Inc.
Publication of MA51620A publication Critical patent/MA51620A/fr
Publication of MA51620B1 publication Critical patent/MA51620B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/027—Organoboranes and organoborohydrides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des composés de formule (I), ou un sel pharmaceutiquement acceptable de ceux-ci, A, Z, B, R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, G<sub>1,</sub> G<sub>2</sub> et G<sub>3</sub> étant tels que définis dans la description. L'invention concerne également une composition pharmaceutiquement acceptable comprenant un composé de formule (I), ou un sel pharmaceutiquement acceptable de celui-ci, ainsi que des procédés d'utilisation d'un composé de formule (I), ou un sel pharmaceutiquement acceptable de celui-ci, destiné à être utilisé dans des méthodes de traitement de maladies cardiaques par inhibition de sarcomes cardiaques.
MA51620A 2018-01-19 2019-01-18 Analogues de dihydrobenzofurane et d'inden en tant qu'inhibiteurs de sarcomes cardiaques MA51620B1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862619643P 2018-01-19 2018-01-19
US201862745724P 2018-10-15 2018-10-15
PCT/US2019/014344 WO2019144041A1 (fr) 2018-01-19 2019-01-18 Analogues de dihydrobenzofurane et d'inden en tant qu'inhibiteurs de sarcomes cardiaques
EP19703917.5A EP3740481B9 (fr) 2018-01-19 2019-01-18 Analogues de dihydrobenzofurane et d'inden en tant qu'inhibiteurs de sarcomes cardiaques

Publications (2)

Publication Number Publication Date
MA51620A MA51620A (fr) 2020-11-25
MA51620B1 true MA51620B1 (fr) 2024-10-31

Family

ID=65324663

Family Applications (1)

Application Number Title Priority Date Filing Date
MA51620A MA51620B1 (fr) 2018-01-19 2019-01-18 Analogues de dihydrobenzofurane et d'inden en tant qu'inhibiteurs de sarcomes cardiaques

Country Status (33)

Country Link
US (4) US10836755B2 (fr)
EP (2) EP3740481B9 (fr)
JP (3) JP7401439B2 (fr)
KR (1) KR102797441B1 (fr)
CN (3) CN117964573B (fr)
AU (2) AU2019208331C1 (fr)
BR (1) BR112020014428A2 (fr)
CA (2) CA3252332A1 (fr)
CL (2) CL2020001871A1 (fr)
CO (1) CO2020009225A2 (fr)
DK (1) DK3740481T5 (fr)
EC (1) ECSP20044709A (fr)
ES (1) ES2986630T3 (fr)
FI (1) FI3740481T3 (fr)
HR (1) HRP20241014T2 (fr)
HU (1) HUE067913T2 (fr)
IL (1) IL276094B2 (fr)
LT (1) LT3740481T (fr)
MA (1) MA51620B1 (fr)
MD (1) MD3740481T3 (fr)
MX (2) MX2020007532A (fr)
MY (1) MY203855A (fr)
NZ (1) NZ765795A (fr)
PH (1) PH12020551090A1 (fr)
PL (1) PL3740481T3 (fr)
PT (1) PT3740481T (fr)
RS (1) RS66042B9 (fr)
SG (1) SG11202006296YA (fr)
SI (1) SI3740481T1 (fr)
SM (1) SMT202400329T1 (fr)
TW (2) TWI835770B (fr)
UY (1) UY38057A (fr)
WO (1) WO2019144041A1 (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117964573B (zh) 2018-01-19 2026-04-14 赛特凯恩蒂克公司 作为心肌节抑制剂的二氢苯并呋喃和茚类似物
WO2020005888A1 (fr) * 2018-06-26 2020-01-02 Cytokinetics, Inc. Inhibiteurs de sarcomères cardiaques
EP3814342B1 (fr) * 2018-06-26 2022-07-27 Cytokinetics, Inc. Inhibiteurs de sarcomères cardiaques
CN112867539B (zh) 2018-08-31 2024-08-06 赛特凯恩蒂克公司 心脏肌小节抑制剂
IL317949A (en) * 2019-05-03 2025-02-01 Praxis Prec Medicines Inc KCNT1 inhibitors and methods of use
RS65611B1 (sr) * 2019-07-17 2024-07-31 Cytokinetics Inc Polimorfi (r)-n-(5-(5-etil-1,2,4-oksadiazol-3-il)-2,3-dihidro-1h-inden-1-il)-1-metil-1h- pir azole-4-karboksamida
LT3999038T (lt) * 2019-07-17 2024-03-25 Cytokinetics, Inc. Širdies sarkomerų inhibitoriaus geriamosios vaistinės formos
CN114667283B (zh) * 2019-07-17 2023-12-26 赛特凯恩蒂克公司 (r)-n-(5-(5-异丙基-1,2,4-噁二唑-3-基)-2,3-二氢-1h-茚-1-基)-2-甲基-2h-四唑-5-甲酰胺的多晶型物
IL300775A (en) 2020-08-28 2023-04-01 Myokardia Inc Treatment methods with myosin modulator
CN112094253B (zh) * 2020-09-10 2023-01-10 株式会社大熊制药 用于制备sglt抑制剂中间体的合成方法
TW202302594A (zh) * 2021-03-04 2023-01-16 美商胞質動力學公司 心臟肌節抑制劑
US20230058927A1 (en) 2021-07-16 2023-02-23 Cytokinetics, Inc. Methods for treating hypertrophic cardiomyopathy
ES3062809T3 (en) 2021-08-03 2026-04-14 Cytokinetics Inc Process for preparing aficamten
WO2023211872A1 (fr) 2022-04-26 2023-11-02 MyoKardia, Inc. Méthode d'administration d'inhibiteurs de myosine
CN119947723A (zh) 2022-07-20 2025-05-06 赛特凯恩蒂克公司 用于治疗非阻塞性肥厚性心肌病的方法
US20240115554A1 (en) 2022-08-04 2024-04-11 Cytokinetics, Incorporated Methods for treating obstructive hypertrophic cardiomyopathy
US20260055100A1 (en) 2022-08-18 2026-02-26 Cytokinetics, Incorporated Indane and coumaran derivatives as fast skeletal muscle myosin inhibitors
WO2024134498A1 (fr) 2022-12-22 2024-06-27 Assia Chemical Industries Ltd. Formes à l'état solide d'aficamten et leur procédé de préparation
CN115894361A (zh) * 2022-12-28 2023-04-04 上海合全药业股份有限公司 一种钯催化合成1-乙酰基-6-氰基-四氢喹啉的方法
CN120712262A (zh) * 2023-03-02 2025-09-26 苏州科睿思制药有限公司 Aficamten的共晶及其制备方法和用途
WO2025096779A2 (fr) 2023-11-01 2025-05-08 Bristol Myers Squibb Company Procédés de traitement avec un inhibiteur de myosine à l'aide de niveaux de protéine
WO2025175141A1 (fr) * 2024-02-16 2025-08-21 Cytokinetics, Incorporated Inhibiteurs de la myosine rapide des muscles squelettiques
WO2025198687A1 (fr) 2024-03-20 2025-09-25 Cytokinetics, Incorporated Méthodes de traitement de maladies cardiaques

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US633499A (en) 1899-06-29 1899-09-19 Oil Well Supply Co Coupling for pipes, tubes, or casings.
US6334997B1 (en) 1994-03-25 2002-01-01 Isotechnika, Inc. Method of using deuterated calcium channel blockers
CN1087725C (zh) 1994-03-25 2002-07-17 同位素技术有限公司 用氘代方法增强药物效果
US5919785A (en) 1996-04-03 1999-07-06 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US6908923B2 (en) 2001-12-21 2005-06-21 Cytokinetics, Inc. Compositions and methods for treating heart failure
US20030158186A1 (en) 2001-12-21 2003-08-21 Fady Malik Compositions and methods for treating heart failure
US6855822B2 (en) * 2002-06-24 2005-02-15 Vivoquest, Inc. Benzo[b]furan dimers
CA2511970C (fr) * 2003-01-14 2012-06-26 Cytokinetics, Inc. Derives de l'uree utiles pour traiter l'insuffisance cardiaque
JP2006516288A (ja) 2003-01-21 2006-06-29 アーケミックス コーポレイション 眼の薬物療法において有用なアプタマー治療薬
US7595322B2 (en) 2003-03-27 2009-09-29 Cytokinetics, Inc. Heterocyclic sulfonamides as modulators of cardiac sarcomeres
BRPI0411673A (pt) * 2003-06-20 2006-08-08 Amgen Inc composto, sal farmaceuticamente aceitável, composição farmacêutica, e, uso de um composto
BRPI0512193B8 (pt) * 2004-06-17 2021-05-25 Cytokinetics Inc composto ou sal farmaceuticamente aceitável, composição farmacêutica, e, uso do composto ou sal
CN101137414A (zh) * 2004-12-31 2008-03-05 欧兰拓制药股份有限公司 多环双酰胺mmp抑制剂
US20060173183A1 (en) * 2004-12-31 2006-08-03 Alantos Pharmaceuticals, Inc., Multicyclic bis-amide MMP inhibitors
AU2006239920A1 (en) 2005-04-22 2006-11-02 Wyeth Dihydrobenzofuran derivatives and uses thereof
US20060293345A1 (en) * 2005-05-20 2006-12-28 Christoph Steeneck Heterobicyclic metalloprotease inhibitors
US7718657B2 (en) 2005-12-16 2010-05-18 Cytokinetics, Inc. Certain indanyl urea modulators of the cardiac sarcomere
RU2318818C1 (ru) 2006-04-12 2008-03-10 Общество С Ограниченной Ответственностью "Исследовательский Институт Химического Разнообразия" Азагетероциклы, комбинаторная библиотека, фокусированная библиотека, фармацевтическая композиция и способ получения (варианты)
SA08290245B1 (ar) 2007-04-23 2012-02-12 استرازينيكا ايه بي مشتقات كربو كساميد جديدة من -n (8-اريل رباعي هيدرو نفثالين غير متجانس- 2- يل) أو -n (5-اريل كرومان غير متجانس -3-يل) لعلاج الألم
US20090192168A1 (en) 2008-01-04 2009-07-30 Alex Muci Compounds, Compositions and Methods
WO2010033701A2 (fr) * 2008-09-19 2010-03-25 Genzyme Corporation Inhibiteurs de la sphingosine kinase 1
BRPI1010600A2 (pt) 2009-05-15 2016-03-15 Novartis Ag aril piridina como inibidores de aldosterona sintase
US8592426B2 (en) * 2011-01-24 2013-11-26 Hoffmann—La Roche Inc. Aryl-benzocycloalkyl amide derivatives
US8759380B2 (en) 2011-04-22 2014-06-24 Cytokinetics, Inc. Certain heterocycles, compositions thereof, and methods for their use
US9493412B2 (en) * 2011-09-27 2016-11-15 Bristol-Myers Squibb Company Pyrrolinone carboxamide compounds useful as endothelial lipase inhibitors
NZ628910A (en) 2012-01-20 2016-02-26 Actelion Pharmaceuticals Ltd Heterocyclic amide derivatives as p2x7 receptor antagonists
WO2014205234A1 (fr) 2013-06-21 2014-12-24 MyoKardia, Inc. Composés de pyrimidinedione substitués par cycloalkyle
SMT202000071T1 (it) 2013-06-21 2020-03-13 Myokardia Inc Composti di pirimidinadione contro le condizioni cardiache
HRP20181109T1 (hr) 2013-12-11 2018-11-02 Biogen Ma Inc. Spojevi biarila korisni za liječenje ljudskih bolesti u onkologiji, neurologiji i imunologiji
WO2015142001A2 (fr) 2014-03-21 2015-09-24 충남대학교산학협력단 Composé doté d'une action cardiotonique et composition pharmaceutique permettant de prévenir ou de traiter l'insuffisance cardiaque et contenant ledit composé
US9663516B2 (en) 2014-12-18 2017-05-30 MyoKardia, Inc. Bicyclic-pyrimidinedione compounds
BR112017015431A2 (pt) * 2015-01-20 2018-01-16 Merck Sharp & Dohme composto, composição farmacêutica, métodos para inibir a formação de trombos no sangue ou tratar uma formação de trombos no sangue, para impedir a formação de trombos no sangue, para tratar tromboembolismo venoso e embolia pulmonar, para tratar trombose venosa profunda e para tratar ataque tromboembólico, e, uso de um composto
PH12021553074A1 (en) 2015-01-22 2023-03-06 Myokardia Inc 4-methylsulfonyl-substituted piperidine urea compounds for the treatment of dilated cardiomyopathy (dcm)
CN105884752B (zh) * 2015-02-13 2018-08-31 山东轩竹医药科技有限公司 并环类回旋酶和拓扑异构酶iv抑制剂
JP6864673B2 (ja) 2015-10-02 2021-04-28 シンジェンタ パーティシペーションズ アーゲー 殺微生物オキサジアゾール誘導体
CN108430997B (zh) 2015-12-17 2021-06-04 先正达参股股份有限公司 杀微生物的噁二唑衍生物
BR112018012378B1 (pt) 2015-12-18 2022-12-20 Syngenta Participations Ag Composto da fórmula (i) e seu uso, composição agroquímica e método de controle ou prevenção de infestação de plantas úteis por microrganismos fitopatogênicos
EP3448519A4 (fr) 2016-04-29 2020-01-22 Board Of Regents, The University Of Texas System Liants de récepteur sigma
WO2017222951A1 (fr) 2016-06-23 2017-12-28 Merck Sharp & Dohme Corp. 5-trifluorométhyl-oxadiazoles substitués en 3-aryle et hétéroaryle en tant qu'inhibiteurs de l'histone désacétylase 6 (hdac6)
CR20190147A (es) 2016-09-27 2019-05-17 Merck Sharp & Dohme DERIVADOS DE CROMANO, ISOCROMANO Y DIHIDROISOBENZOFURANOS COMO MODULADORES ALOSTÉRICOS NEGATIVOS DE mGluR2, COMPOSICIONES Y SU USO
WO2018089433A1 (fr) 2016-11-08 2018-05-17 Navitor Pharmaceuticals, Inc. Inhibiteurs de mtorc phényle et leurs utilisations
JP2020023442A (ja) 2016-12-19 2020-02-13 住友化学株式会社 オキサジアゾール化合物及び植物病害防除方法
US20200000822A1 (en) 2017-02-23 2020-01-02 Board Of Regents, The University Of Texas System Methods of treatment for cancer, sterol homeostasis, and neurological diseases
EP3590929B1 (fr) 2017-02-28 2021-09-15 Medshine Discovery Inc. Composé spiro et son utilisation
SI3661514T1 (sl) 2017-08-04 2026-01-30 MyoKardia, Inc. Mavacamten za uporabo pri zdravljenju hipertrofične kardiomiopatije
CN117964573B (zh) 2018-01-19 2026-04-14 赛特凯恩蒂克公司 作为心肌节抑制剂的二氢苯并呋喃和茚类似物
MD3762368T2 (ro) 2018-03-08 2022-07-31 Incyte Corp Compuși diol aminopirazină ca inhibitori ai PI3K-Y
US10710994B2 (en) 2018-03-19 2020-07-14 Genentech, Inc. Oxadiazole transient receptor potential channel inhibitors
EP3814342B1 (fr) 2018-06-26 2022-07-27 Cytokinetics, Inc. Inhibiteurs de sarcomères cardiaques
WO2020005888A1 (fr) 2018-06-26 2020-01-02 Cytokinetics, Inc. Inhibiteurs de sarcomères cardiaques
CN112867539B (zh) 2018-08-31 2024-08-06 赛特凯恩蒂克公司 心脏肌小节抑制剂
IL279810B2 (en) 2018-08-31 2025-03-01 Xenon Pharmaceuticals Inc Heteroaryl-modified sulfonamide compounds and their use as medicinal agents
RS65611B1 (sr) 2019-07-17 2024-07-31 Cytokinetics Inc Polimorfi (r)-n-(5-(5-etil-1,2,4-oksadiazol-3-il)-2,3-dihidro-1h-inden-1-il)-1-metil-1h- pir azole-4-karboksamida
CN114667283B (zh) 2019-07-17 2023-12-26 赛特凯恩蒂克公司 (r)-n-(5-(5-异丙基-1,2,4-噁二唑-3-基)-2,3-二氢-1h-茚-1-基)-2-甲基-2h-四唑-5-甲酰胺的多晶型物
LT3999038T (lt) 2019-07-17 2024-03-25 Cytokinetics, Inc. Širdies sarkomerų inhibitoriaus geriamosios vaistinės formos
IL300775A (en) 2020-08-28 2023-04-01 Myokardia Inc Treatment methods with myosin modulator
TW202302594A (zh) 2021-03-04 2023-01-16 美商胞質動力學公司 心臟肌節抑制劑
US20230058927A1 (en) 2021-07-16 2023-02-23 Cytokinetics, Inc. Methods for treating hypertrophic cardiomyopathy
ES3062809T3 (en) 2021-08-03 2026-04-14 Cytokinetics Inc Process for preparing aficamten
WO2023211872A1 (fr) 2022-04-26 2023-11-02 MyoKardia, Inc. Méthode d'administration d'inhibiteurs de myosine

Also Published As

Publication number Publication date
DK3740481T5 (da) 2025-05-05
AU2019208331A1 (en) 2020-07-16
SMT202400329T1 (it) 2024-09-16
US20210147399A1 (en) 2021-05-20
EP4491622A3 (fr) 2025-04-30
RS66042B1 (sr) 2024-11-29
JP2023169374A (ja) 2023-11-29
ES2986630T3 (es) 2024-11-12
US20250059173A1 (en) 2025-02-20
PL3740481T3 (pl) 2024-11-04
SI3740481T1 (sl) 2024-09-30
CN117964573A (zh) 2024-05-03
PH12020551090A1 (en) 2021-09-01
ECSP20044709A (es) 2020-10-30
RS66042B9 (sr) 2025-05-30
US12065436B2 (en) 2024-08-20
US20230119665A1 (en) 2023-04-20
EP3740481B1 (fr) 2024-06-26
EP3740481B9 (fr) 2024-10-23
DK3740481T3 (da) 2024-07-08
JP2021511331A (ja) 2021-05-06
UY38057A (es) 2019-08-30
WO2019144041A1 (fr) 2019-07-25
CL2020001871A1 (es) 2020-10-23
TWI835770B (zh) 2024-03-21
FI3740481T3 (fi) 2024-07-30
US10836755B2 (en) 2020-11-17
CL2022001091A1 (es) 2023-01-20
KR102797441B1 (ko) 2025-04-22
KR20200112895A (ko) 2020-10-05
CN117924208A (zh) 2024-04-26
MX2022014312A (es) 2022-12-07
HUE067913T2 (hu) 2024-11-28
EP4491622A2 (fr) 2025-01-15
CO2020009225A2 (es) 2020-08-10
MX2020007532A (es) 2020-09-09
LT3740481T (lt) 2024-08-26
FI3740481T9 (fi) 2025-05-07
MY203855A (en) 2024-07-22
IL276094B2 (en) 2023-08-01
JP2025106500A (ja) 2025-07-15
US11472796B2 (en) 2022-10-18
MD3740481T2 (ro) 2024-12-31
CN117964573B (zh) 2026-04-14
AU2019208331B2 (en) 2024-05-02
CA3252332A1 (fr) 2025-06-04
AU2024204859A1 (en) 2024-08-01
NZ765795A (en) 2026-01-30
EP3740481A1 (fr) 2020-11-25
IL276094B1 (en) 2023-04-01
BR112020014428A2 (pt) 2020-12-01
IL276094A (en) 2020-08-31
CN111757875B (zh) 2024-01-09
HRP20241014T2 (hr) 2025-05-23
SG11202006296YA (en) 2020-08-28
TWI898447B (zh) 2025-09-21
HRP20241014T1 (hr) 2024-11-08
JP7401439B2 (ja) 2023-12-19
TW202436291A (zh) 2024-09-16
CA3087283A1 (fr) 2019-07-25
MD3740481T3 (ro) 2025-06-30
CN111757875A (zh) 2020-10-09
TW201940471A (zh) 2019-10-16
AU2019208331C1 (en) 2024-11-14
CA3087283C (fr) 2026-01-27
US20190256504A1 (en) 2019-08-22
MA51620A (fr) 2020-11-25
PT3740481T (pt) 2024-09-13

Similar Documents

Publication Publication Date Title
MA52360B1 (fr) Dérivés de 2-amino-pyridine ou de 2-amino-pyrimidine utilisés en tant qu&#39;inhibiteurs de kinases dépendantes des cyclines
MA49956B1 (fr) Composés de pyrimidine utilisés en tant qu&#39;inhibiteurs de kinase jak
MA55533B1 (fr) Agents de modulation de régulateur de conductance transmembranaire de fibrose kystique
MA51530B1 (fr) Composés cycliques fondus
MA52948B1 (fr) Composés
MA57412B1 (fr) Benzopyrrole substitués et inhibiteurs du complément structurellement apparentés
WO2019035864A8 (fr) Activateurs de la pyruvate kinase destinés à être utilisés dans le traitement de troubles sanguins
MA42678B1 (fr) Nouveaux analogues nucléosidiques substitués à cycle aromatique bicyclique 6-6 pour une utilisation en tant qu&#39;inhibiteurs de prmt5
MA47970B1 (fr) Composé inhibiteur de jak à base d&#39;imidazo-pipéridine fusionnée
MA54229B1 (fr) Composés et compositions destinés au traitement d&#39;états pathologiques associés à une activité de nlrp
EA202092253A1 (ru) Замещенные производные имидазолидин-2-она в качестве ингибиторов prmt5
MA53399B1 (fr) Pyrazoles substitués en tant qu`inhibiteurs de la kallicréine plasmatique humaine
MA51431B1 (fr) Dérivés d&#39;oxy-fluoropipéridine utilisés en tant qu&#39;inhibiteur de kinase
MA43979B1 (fr) Dérivés de 1h-indazole-3-carboxamide et composés similaires en tant qu&#39;inhibiteurs du facteur d pour le traitement de maladies characterisés par une activité aberrante du système complémentaire, comme p.E. Troubles immunologiques
MA29335B1 (fr) Derives de n-(n-sulfonylaminomethyl) cyclopropanecarboxamide utiles pour le traitement de la douleur
MA40111A1 (fr) Dérivés du tétrahydronaphtalène inhibant la protéine mcl-1
MA54386B1 (fr) Modulateurs de trex1
MA46101B1 (fr) Modulateurs allostériques positifs du récepteur muscarinique m1
MA32483B1 (fr) Compose heterocyclique et son utilisation
MA55046B1 (fr) Utilisation de dérivés d&#39;indole n-substitués comme modulateurs des récepteurs des pge2
MA46229B1 (fr) Composés d&#39;hétéroaryle carboxamide en tant qu&#39;inhibiteurs de ripk2
MA49127B1 (fr) Dérivés d&#39;indole n-substitués
MA50013B1 (fr) Analogues de benzoazépine utilisés en tant qu&#39;agents inhibiteurs de la tyrosine kinase de bruton
CA3242974A1 (fr) Lipide et composition servant a l&#39;administration
MA43052B1 (fr) Inhibiteurs de la kallicréine plasmatique humaine